SEW2871

SEW2871 is a **selective agonist** of the sphingosine-1-phosphate receptor 1 (S1P1), functioning as a small molecule modulator that does not require phosphorylation for activity and is structurally distinct from sphingosine-1-phosphate itself[1][7]. It has been broadly used as a research tool to study the immunomodulatory and neuroprotective actions of S1P1 activation. In preclinical models, SEW2871 administration has shown efficacy in ameliorating T-cell-mediated inflammation, reducing neuroinflammation and dopaminergic neuronal loss in Parkinson’s disease models, preventing blood-brain barrier leakage and brain injury, and offering renal protection in ischemia–reperfusion injury[1][4][6][8]. SEW2871 can also modulate seizure susceptibility and neuronal physiology. Despite positive findings in some CNS and renal disease models, severe cardiac side effects and limited protective efficacy have been observed in settings such as sepsis[2]. The agent is primarily used in experimental and preclinical research, and there is no evidence of clinical development by commercial pharmaceutical companies.